Number of shares and votes in EQT
Cancellation of 6,899,011 ordinary shares held in treasury by EQT
The cancellation was resolved by the Annual Shareholders' Meeting 2025
As of 30 May 2025, there are 1,177,185,346 shares outstanding in EQT
STOCKHOLM, May 30, 2025 /PRNewswire/ -- The total number of shares and votes in EQT AB (publ) ("EQT") has decreased by 6,899,011 shares and votes during May 2025 as a result of a cancellation of 6,899,011 ordinary shares held in treasury by EQT. The cancellation was resolved by the Annual Shareholders' Meeting 2025 on 27 May 2025, in line with EQT's intention to off-set over time the dilution impact from shares delivered to participants in EQT's Share and Option Programs.
The number of shares and votes in EQT as of 30 May 2025 is set out in the table below.
Ordinary shares
Class C shares1
Total
Number of issued shares2
1,234,611,900 (1,234,611,900 votes)
496,056 (49,605.6 votes)
1,235,107,956 (1,234,661,505.6 votes)
Number of shares owned by EQT AB3
57,922,610
-
57,922,610
Number of outstanding shares
1,176,689,290 (1,176,689,290 votes)
496,056 (49,605.6 votes)
1,177,185,346 (1,176,738,895.6 votes)
1 Carry one tenth (1/10) of a vote
2 Total number of shares in EQT AB, i.e. including the number of shares owned by EQT AB and the number of shares outstanding
3 EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders' meetings
This press release is published for regulatory reasons.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15EQT Press Office, press@eqtpartners.com, +46 8 506 55 334
This is information that EQT AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 18:00 CET on 30 May 2025.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/number-of-shares-and-votes-in-eqt,c4157206
The following files are available for download:
https://mb.cision.com/Main/87/4157206/3479583.pdf
EQT - Number of shares and votes (30 May 2025)
https://news.cision.com/eqt/i/eqt-group,c3413963
EQT Group
View original content:https://www.prnewswire.co.uk/news-releases/number-of-shares-and-votes-in-eqt-302469735.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
PingPong Expands Leading B2B Cross-Border Payments Platform Into Malaysia, Further Unlocking Southeast Asia For Enterprise Clients
PingPong has been granted a Money Services Business Licence Class B from Malaysia's central bank, Bank Negara Malaysia, unlocking a USD $445 billion economy for enterprises, financial institutions, and SaaS companies expanding into and out of Malaysia. This follows PingPong's recent expansion into Indonesia and existing presence in Vietnam, Thailand, Singapore, and the Philippines, further expanding PingPong's comprehensive portfolio of over 60 global licences. KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- PingPong, the world-leading provider of cross-border embedded payment solutions for enterprises, is pleased to announce that it has been granted a Money Services Business Licence from Malaysia's central bank, Bank Negara Malaysia. This latest licence further enhances PingPong's extensive portfolio of over 60 global licences, unlocking even more cross-border opportunities for enterprises on PingPong's platform. Malaysia offers significant growth opportunities for enterprises looking to scale in Southeast Asia. Its GDP is expected to reach $445 billion USD by the end of 2025 and grow by 33% by 2030, reaching $600 billion USD. International trade is a significant part of Malaysia's wealth, valued at 132% of GDP in 2023. Financial services and fintech companies are thriving across Southeast Asia, with Malaysia emerging as a key player. The country ranks third in the region in terms of the number of fintech companies it has, and it is poised for significant growth. Malaysia's fintech sector is projected to double, from $54 billion USD in 2025 to $111 billion USD by 2030, reflecting a robust compound annual growth rate (CAGR) of 16%. Its strategic location, high digital adoption rate, and robust financial sector have made it one of the key growing countries in Southeast Asia. Jianqin Shu, Partner and APAC General Manager at PingPong, said, "As one of the most strategically positioned and rapidly growing economies in Southeast Asia, Malaysia presents an incredible opportunity for enterprises scaling their global operations. Securing a Money Services Business licence positions PingPong at the heart of this growth, empowering us to support Malaysia's expanding fintech and financial services ecosystem, meeting the rising demand for efficient, compliant cross-border payment solutions. This milestone enables us to extend our global reach further and provide enterprises with end-to-end, one-stop payment services." This approval from Bank Negara Malaysia further adds to PingPong's significant portfolio of over 60 global licences across the United States, EU, UK, Hong Kong, mainland China, Canada, Australia, Japan, Singapore, Indonesia and other countries and regions worldwide. About us PingPong was founded in New York in 2015, with the goal of solving the immense challenge of scaling enterprise businesses globally. Fast forward to today, and PingPong has become one of the world's leading global cross-border payments platforms, processing more than $250 billion USD. Our API-first cross-border payments platform integrates with enterprises to send, manage, and receive money faster on a global scale. PingPong currently has 37 offices in 15 countries and 1,500 employees. Our international presence helps businesses solve complex payment needs in every major economy across all time zones. Logo - Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
Yahoo
12 hours ago
- Yahoo
HORIZON PETROLEUM PROVIDES AN OPERATIONS UPDATE OF ITS PREPARATION FOR FIRST PRODUCTION IN POLAND
CALGARY, AB, June 1, 2025 /PRNewswire/ - Horizon Petroleum Ltd. (the "Company" or "Horizon") (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to provide an operations update on progress made towards first production from its cornerstone Lachowice gas development in the Bielsko-Biala concession, southern Poland. David Winter, CEO of the Horizon commented: " We are pleased with the continuing progress in our operations towards first production from the Lachowice 7 well. Board and Management recognise the efforts of our operating team in Poland in ensuring that the initial development program is executed as planned. We also recognise the very positive relationships that we enjoy with our neighbours at Lachowice, and the positive contributions from our contractors, local authorities and government. We look forward to our continuing work with all stakeholders and will update shareholders as the initial development program progresses". Assuming a successful workover result, gas and/or electrical power sales from the Lachowice 7 (L7) well will provide the Company with its first cashflow and will provide a long-term test of the production performance of the naturally fractured, Devonian aged, limestone and dolomite reservoirs in the L7 well. Preparatory work for the L7 workover is progressing on schedule: The Environmental Impact Assessment (EIA) Permit for the L7 workover has been approved by the Ministry of Climate and the Environment (the "Ministry"). With the funds from the recent successful debenture financing, long lead time materials and services have been sourced and ordered with expected deliveries in August and September. These materials include the tubing, wellhead and completion equipment. The Company has received confirmation from its electrical contractor that the local utility company will move the power line that crosses the L7 wellsite by the end of June. Final civil engineering design for the wellsite and access road has been completed and tendering for the construction works to be awarded in the next 3-4 weeks. Wellsite and access road construction to commence in July once the above-mentioned electricity line has been moved. The Company is working with a local service provider to choose the appropriate rig for the workover, now scheduled to commence in September with long-term production testing of the well in October. Early Production System (EPF) The Company continues the work towards finalizing the early production scheme for the initial development at the L7 well following the workover and testing. As previously disclosed, the Company contracted a local electrical engineering company and a mechanical engineering company to review options to monetize gas production from the initial development at L7 and the full field development Lachowice gas field. The reviews and investigations are largely completed: Gas to Power: The company has identified two access points into the local electricity transmission grids. The first with 2MW capacity is located with 300m of the L7 wellsite. The second with 4MW capacity is located approximately 1km from the L7 wellsite. Horizon has made an application to secure the 2MW capacity that will be the first tie-in point for G2P. The company continues to work towards securing the 4MW at the second location. The preliminary design of the gas processing facility that will be required to separate the liquid condensate and any free water from the L7 gas stream has been completed. The Company has commenced sourcing the required vessels and other process equipment. Work on the EIA for the production facility is underway targeting submission in mid-June. Full Field Development Plan The Company has commenced the preliminary work for the EIA for the planned 100km2 3D seismic survey over the Lachowice gas field. A third-party evaluation has identified a high-pressure gas network tie-in point approximately 14 km northeast of L7, half the distance of the previous plan, which will result in reduced pipeline costs and faster approvals. Takeaway capacities have been confirmed and are consistent with Horizon's short and long-term forecast production volumes. The Company has commenced discussions with pipeline operator and owner to secure access and pipeline capacity. The Company will shortly commence the initial work on the EIA for the full field development facility site and commence the process to rezone the land for industrial use. Lachowice 7 Well Workover Operations Program The L7 workover is scheduled to be conducted in September/October of this year subject to receiving the necessary long lead items, equipment and services as planned. A detailed program has been completed and application to the Polish Mining authority for the program will be submitted shortly. The workover program will consist of: Upgrade the wellhead to execute the workover and eventual production. Drill out a surface cement plug and downhole mechanical plug in the wellbore. Pressure test the existing well casing to ensure wellbore security and integrity Drill and recover an existing packer located above the zone that originally tested up to 8.9mmscf/d gas Reperforate, acid stimulation and production test of this same zone Complete the well for production in anticipation of the EPF to be installed on site in first half 2026. The Company is targeting gas/electricity sales and first cash flow by the first half of 2026. About Horizon Petroleum Ltd. Calgary-based Horizon is focused on the appraisal and development of natural gas and oil reserves in Europe. The Management and Board of Horizon consist of oil & gas professionals with significant international experience. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward-looking statements" or "forward-looking information" (collectively referred to herein as "forward-looking statements") within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Horizon. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur or be achieved. This press release contains forward-looking statements pertaining to, among other things the timing of re-entry of the well, the moving of the infrastructure in the area, timing of sales gas, and other operational matters in this news release, all of which are subject to change. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Horizon and described in the forward-looking information contained in this press release. Although Horizon believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. View original content to download multimedia: SOURCE Horizon Petroleum Ltd. Sign in to access your portfolio
